Vanda Pharmaceuticals Inc (LTS:0LKB)
$ 5.0312 -0.1487 (-2.87%) Market Cap: 293.87 Mil Enterprise Value: -74.45 Mil PE Ratio: 0 PB Ratio: 0.54 GF Score: 64/100

Vanda Pharmaceuticals Inc at JPMorgan Healthcare Conference Transcript

Jan 09, 2024 / 05:45PM GMT
Release Date Price: $10.39
Unidentified Analyst

Hello, everyone. My name is (inaudible). I'm an associate with JPMorgan. It's my pleasure to introduce Kevin from Vanda. Before we get started, just heads up, we won't be holding Q&A at the end.

And with that, Kevin, go ahead.

Kevin Patrick Moran
Vanda Pharmaceuticals Inc. - Senior VP, CFO & Treasurer

Thank you very much. And thank you to the entire JPMorgan team for having us speak -- very excited to speak to you about recent developments of the company and our upcoming milestones for 2024. Looking at our forward-looking statements, investors should be familiar with our forward-looking statements and the risks associated with Vanda stock. Vanda Pharmaceuticals is a leading global biopharmaceutical company dedicated to innovating in the service of people's pursuit of happiness. We now have 3 commercialized products with our recent acquisition of PONVORY, which I'll touch on in greater detail as we step through the presentation.

Our commercialized products include HETLIOZ, which is both the oral capsule formulation of

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot